Results 21 to 30 of about 18,928 (205)

Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention

Российский кардиологический журнал, 2020
Aim. To conduct a cost analysis of using novel inhibitors of P2Y 12 (prasugrel and ticagrelor) in patients with acute coronary syndrome (ACS) in the Russian healthcare system.Material and methods.
I. N. Dyakov, E. A. Ushkalova
doaj   +1 more source

P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

Journal of Interventional Cardiology, 2023
Background. Randomized trials have shown superiority of the novel P2Y12 inhibitors over clopidogrel in patients with acute coronary syndrome (ACS), but clinical benefit in the community remains controversial.
Amit Sachdeva, Ratnabhushan Mutyala, Neha Mantri, Shiyun Zhu, Edward McNulty, Matthew Solomon   +5 more
doaj   +1 more source

The Use of Prasugrel and Ticagrelor in Pipeline Flow Diversion [PDF]

, 2018
Background: Despite the routine clopidogrel/aspirin anti-platelet therapy, complications like thromboembolism, continue to be encountered with PED.
Atallah, MD, Elias, Bekelis, MD, Kimon, Chalouhi, MD, Nohra, Eller, MD, Gorge, Hasan, MD, David, Jabbour, Pascal, MD, Rosenwasser, MD, MBA, FACS, FAHA MD, Robert H., Saad, MD, Hassan, Stidd, MD, David, Tjoumakaris, MD, Stavropoula   +9 more
core   +2 more sources

Coming safely to a stop : a review of platelet activity after cessation of antiplatelet drugs [PDF]

, 2015
Funding Isobel Ford is an employee of the University of Aberdeen. The research for the writing of this review received no specific grant from any funding agency in the public, commercial, or not-forprofit sectorsPeer ...
Ford, Isobel
core   +1 more source

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel

Thrombosis Journal, 2018
Background Although prasugrel exerts stronger antiplatelet effects compared with clopidogrel, the factors affecting platelet reactivity under prasugrel have not been fully determined. This study aimed to find the novel mechanistic differences between two
Satoshi Niijima, Tsukasa Ohmori, Kazuomi Kario   +2 more
doaj   +1 more source

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]

, 2018
© 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki, Farag, Mohamed, Gorog, Diana Adrienne, Spinthakis, Nikolaos   +3 more
core   +2 more sources

Platelet Blockage: Prasugrel versus Ticagrelor: Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5

Journal of the Practice of Cardiovascular Sciences, 2019
The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 trial randomized patients with acute coronary syndrome for whom invasive treatment was planned to ticagrelor versus prasugrel.
Venkatakrishnan Ramakumar
doaj   +1 more source

Bivalirudin started during emergency transport for primary PCI. [PDF]

, 2013
BACKGROUND: Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI).
Berg, J. van den, Bernstein, D., Clayton, T., Clemmensen, P., Coste, P., Deliargyris, E.N., Eggink, G.J., et al., Goldstein, P., Grunsven, P. van, Hamm, C.W., Hamon, M., Hof, A. van't, Huber, K., Lapostolle, F., Nef, H., Nibbe, L., Orto, M. Campo dell', Pocock, S., Prats, J., Schuette, D., Soulat, L., Steg, P.G., Steinmetz, J., Verheugt, F.W.A., Zeymer, U.   +25 more
core   +1 more source

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]

, 2018
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M, Hirsh J, Ibanez B, Mega JL, Park KW, Suh JW, Valgimigli M   +6 more
core   +3 more sources

Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention. [PDF]

, 2017
BackgroundElevated fibrinogen is associated with short-term major adverse cardiovascular events (MACE) after percutaneous coronary intervention, but the relation with late MACE is unknown.Methods and resultsBaseline demographics and 2-year MACE were ...
Ang, Lawrence, Behnamfar, Omid, Lin, Felice, Mahmud, Ehtisham, Palakodeti, Samhita, Patel, Mitul P, Pourdjabbar, Ali, Reeves, Ryan R   +7 more
core   +1 more source